Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icalcaprant in Bipolar Depression
NCT06696755Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of icalcaprant in bipolar I disorder and Bipolar II disorder (BP-II) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 6 weeks and Adverse Events at 10 weeks. Started Feb 2026; status: recruiting.
02
Drugs
icalcaprant
03
Conditions
bipolar I disorderBipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT06696755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696755.